Please assess the completion status of the following clinical trial:

Trial Title: To Investigate Efficacy and Safety of a Single Injection of Org 36286 for Ovarian Stimulation Using Daily Recombinant FSH as Reference (Ensure)(P05690/MK-8962-001)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females of couples with an indication for COS and IVF or ICSI;~* \>=18 and \<= 36 years of age at the time of signing informed consent;~* Body weight \<= 60 kg and BMI \>= 18 and \<= 32 kg/m\^2;~* Normal menstrual cycle length: 24-35 days;~* Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);~* Willing and able to sign informed consent.~Exclusion Criteria:~* History of/or any current (treated) endocrine abnormality;~* History of ovarian hyper-response or ovarian hyperstimulation syndrome~(OHSS);~* History of/or current polycystic ovary syndrome (PCOS);~* More than 20 basal antral follicles \<11 mm (both ovaries combined) as measured on USS in the early follicular phase (menstrual cycle day 2-5);~* Less than 2 ovaries or any other ovarian abnormality (including endometrioma \> 10 mm; visible on USS);~* Presence of unilateral or bilateral hydrosalphinx (visible on USS);~* Presence of any clinically relevant pathology affecting the uterine cavity or fibroids \>= 5 cm;~* More than three unsuccessful IVF cycles since the last established ongoing~pregnancy (if applicable);~* History of non- or low ovarian response to FSH/hMG treatment;~* History of recurrent miscarriage (3 or more, even when unexplained);~* FSH \> 12 IU/L or LH \> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);~* Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase;~* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts);~* Recent history of/or current epilepsy, HIV infection, diabetes, cardiovascular,~gastro-intestinal, hepatic, renal or pulmonary disease;~* Abnormal karyotyping of the patient or her partner (if karyotyping is performed);~* Smoking more than 5 cigarettes per day;~* History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;~* Previous use of Org 36286;~* Use of hormonal preparations within 1 month prior to randomization;~* Hypersensitivity to any of the concomitant medication prescribed as part of the treatment regimen in this protocol;~* Administration of investigational drugs within three months prior to signing informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: f

Study Arms:
- corifollitropin alfa 100 µg (Type: EXPERIMENTAL): Participants received a single subcutaneous (SC) injection of corifollitropin alfa 100 μg (Org 36286) on Day 2 or 3 of the menstrual cycle and daily placebo-recombinant Follicle Stimulating Hormone (recFSH) injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including Day of Human Chorion Gonadotropin (hCG) administration. Participants also received Gonadotropin Releasing Hormone (GnRH) antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG (10,000 or 5,000 IU/USP). Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day by intramuscular \[IM\] injection), starting on day of oocyte pick-up (OPU) and continuing for at least 6 weeks or up to menses.
- recFSH 150 IU (Type: ACTIVE_COMPARATOR): Participants in the reference group received a single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle and daily SC recFSH 150 IU injections (7 total) from Stimulation Day 1 up to and including Stimulation Day 7. Participants also received open-label recFSH (up to 200 IU/day) from Stimulation Day 8 onwards, up to and including the day of hCG (10,000 or 5,000 IU/USP) administration. Participants also received the GnRH antagonist ganirelix (0.25 mg) once daily SC starting on Stimulation Day 5 up to and including the Day of hCG. Participants also received progesterone (at least 600 mg/day vaginally or 50 mg/day IM), starting on the day of OPU and continuing for at least 6 weeks or up to menses.

Based on this trial design, predict the completion outcome and termination type (if applicable).